| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Natural anti-diabetic
Sequoyitol does not have a well-defined single pharmacological target, as it is a natural cyclitol with hypoglycemic activity. It has been shown to lower blood glucose and improve glucose tolerance, suggesting that it may modulate glucose metabolism and insulin sensitivity. The compound's mechanisms of action may involve activation of insulin signaling pathways, enhancement of glucose uptake, or inhibition of glucose production. However, its specific molecular targets have not been fully characterized. Sequoyitol is also studied for its potential effects on other metabolic pathways. |
|---|---|
| ln Vitro |
Sequoyitol demonstrates in vitro activity related to its hypoglycemic effects. Studies have shown that Sequoyitol can lower blood glucose and improve glucose tolerance in cellular models of glucose metabolism. The compound's effects on glucose uptake and insulin signaling may be mediated through activation of AMPK or other metabolic regulators. However, detailed in vitro activity data for Sequoyitol are limited, as most studies focus on its effects in animal models or its use as a reference standard.
|
| ln Vivo |
Sequoyitol decreases blood glucose, improves glucose intolerance, and enhances insulin signaling in ob/ob mice. The aim of this study was to investigate the effects of sequoyitol on diabetic nephropathy in rats with type 2 diabetes mellitus and the mechanism of action. Diabetic rats, induced with a high-fat diet and a low dose of streptozotocin, and were administered sequoyitol (12.5, 25.0, and 50.0 mg·(kg body mass)(-1)·d(-1)) for 6 weeks. The levels of fasting blood glucose (FBG), serum insulin, blood urea nitrogen (BUN), and serum creatinine (SCr) were measured. The expression levels of p22(phox), p47(phox), NF-κB, and TGF-β1 were measured using immunohistochemisty, real-time PCR, and (or) Western blot. The total antioxidative capacity (T-AOC), as well as the levels of malondialdehyde (MDA) and reactive oxygen species (ROS) were also determined. The results showed that sequoyitol significantly decreased FBG, BUN, and SCr levels, and increased the insulin levels in diabetic rats. The level of T-AOC was significantly increased, while ROS and MDA levels and the expression of p22(phox), p47(phox), NF-κB, and TGF-β1 were decreased with sequoyitol treatment both in vivo and in vitro. These results suggested that sequoyitol ameliorates the progression of diabetic nephropathy in rats, as induced by a high-fat diet and a low dose of streptozotocin, through its glucose-lowering effects, antioxidant activity, and regulation of TGF-β1 expression.[1]
Sequoyitol has demonstrated in vivo hypoglycemic activity in animal models. It has been shown to lower blood glucose and improve glucose tolerance in diabetic animal models, suggesting potential therapeutic applications for diabetes. The compound's low toxicity makes it an attractive candidate for further research. However, comprehensive in vivo studies evaluating its pharmacokinetic properties, efficacy, and safety are limited. Further research is needed to fully characterize its in vivo effects and potential therapeutic applications. |
| Enzyme Assay |
In vitro enzyme/receptor binding experiments for Sequoyitol are not typical, as it is a natural cyclitol with hypoglycemic activity rather than a well-defined pharmacologically active compound. Studies may involve measuring its effects on glucose uptake in cultured cells or its ability to activate insulin signaling pathways. The compound can also be used as a reference standard in analytical chemistry for the identification and quantification of inositol derivatives in plant extracts. Its chemical properties are characterized using standard analytical methods such as HPLC and mass spectrometry.
|
| Cell Assay |
In vitro cellular experiments for Sequoyitol typically involve studying its effects on glucose metabolism in cell lines such as hepatocytes, adipocytes, or skeletal muscle cells. Cells are treated with the compound, and glucose uptake, glycogen synthesis, or insulin signaling are measured. The compound's effects on cell viability and proliferation are also assessed. The hypoglycemic activity of Sequoyitol is evaluated in these cellular models. However, detailed studies on Sequoyitol are limited, as most research focuses on its effects in animal models.
|
| Animal Protocol |
In vivo animal experiments for Sequoyitol typically involve administering the compound to diabetic or normal rodents via oral gavage or intraperitoneal injection. Blood glucose levels are measured at various time points to assess the compound's hypoglycemic effects. Glucose tolerance tests are performed to evaluate its ability to improve glucose tolerance. The compound's effects on body weight, insulin levels, and other metabolic parameters are also assessed. These studies have shown that Sequoyitol has hypoglycemic activity with low toxicity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Sequoyitol have not been extensively characterized. With a molecular weight of 194.18 and moderate water solubility, the compound is expected to be absorbed from the gastrointestinal tract. However, detailed studies on its absorption, distribution, metabolism, and excretion are limited. The compound's low toxicity is a favorable property for potential in vivo applications. Further pharmacokinetic studies would be required to assess its potential for therapeutic use.
|
| Toxicity/Toxicokinetics |
Toxicological data for Sequoyitol indicate that it has low toxicity. In vivo studies have shown that Sequoyitol can lower blood glucose without significant adverse effects. Comprehensive toxicology studies, including acute and chronic toxicity, have not been extensively reported. Standard safety precautions for handling natural products apply, including the use of personal protective equipment and working in a well-ventilated area. The compound is not intended for human consumption without further research.
|
| References | |
| Additional Infomation |
1D-5-O-methylinositol belongs to the methylinositol class of compounds. Its structure is cyclohexane-1,2,3,4,5-pentanol with a methoxy group substituted at the 6-position (1R,2S,3r,4R,5S,6r-stereoisomer). It is a plant metabolite. It has been reported that 1D-5-O-methylinositol is found in Nephrolepis cordifolia, soybean (Glycine max), and other organisms with relevant data.
Sequoyitol is a research compound that has not entered clinical trials or received regulatory approval for therapeutic use. It is primarily used as a research tool to study the hypoglycemic effects of inositol derivatives and their potential applications for diabetes. The compound's ability to lower blood glucose and improve glucose tolerance, combined with its low toxicity, makes it a valuable candidate for further pharmacological development. Additional research is needed to fully elucidate its mechanisms of action and evaluate its potential therapeutic applications. |
| Molecular Formula |
C7H14O6
|
|---|---|
| Molecular Weight |
194.18
|
| Exact Mass |
194.079
|
| CAS # |
523-92-2
|
| PubChem CID |
439990
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
317.2±42.0 °C at 760 mmHg
|
| Flash Point |
145.6±27.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| Source |
Nephrolepis cordifolia, Glycine max
|
| LogP |
-0.74
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1[C@@H]([C@H](C([C@H]([C@@H]1O)O)O)O)O
|
| InChi Key |
DSCFFEYYQKSRSV-MVWKSXLKSA-N
|
| InChi Code |
InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2?,3-,4+,5+,6-,7?
|
| Chemical Name |
(1S,2R,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol
|
| Synonyms |
Sequoyitol; 523-92-2; 5-O-Methyl-myo-inositol; 1D-5-O-Methyl-myo-inositol; O-Methyl-scyllo-inositol; 1-O-Methyl-scyllo-inositol; (1R,2S,4R,5S)-6-methoxycyclohexane-1,2,3,4,5-pentol; (1S,2R,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~514.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (514.99 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL | |
| 5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL | |
| 10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
